Literature DB >> 23301633

The adenosine A2A receptor agonist CGS 21680 decreases ethanol self-administration in both non-dependent and dependent animals.

Hakim Houchi1, Wolfgang Persyn, Rémi Legastelois, Mickaël Naassila.   

Abstract

There is emerging evidence that the adenosinergic system might be involved in drug addiction and alcohol dependence. We have already demonstrated the involvement of A2A receptors (A2AR) in ethanol-related behaviours in mice. Here, we investigated whether the A2AR agonist CGS 21680 can reduce ethanol operant self-administration in both non-dependent and ethanol-dependent Wistar rats. To rule out a potential involvement of the A1R in the effects of CGS 21680, we also tested its effectiveness to reduce ethanol operant self-administration in both heterozygous and homozygous A1R knockout mice. Our results demonstrated that CGS 21680 (0.065, 0.095 and 0.125 mg/kg, i.p.) had a bimodal effect on 10% ethanol operant self-administration in non-dependent rats. The intermediate dose was also effective in reducing 2% sucrose self-administration. Interestingly, the intermediate dose reduced 10% ethanol self-administration in dependent animals more effectively (75% decrease) when compared with non-dependent animals (57% decrease). These results suggest that the A2AR are involved in CGS 21680 effects since the reduction of ethanol self-administration was not dependent upon the presence of A1R in mice. In conclusion, our findings demonstrated the effectiveness of the A2AR agonist CGS 21680 in a preclinical model of alcohol addiction and suggested that the adenosinergic pathway is a promising target to treat alcohol addiction.
© 2013 The Authors, Addiction Biology © 2013 Society for the Study of Addiction.

Entities:  

Keywords:  A2A receptor; adenosine; agonist; alcohol dependence; knockout; reward

Mesh:

Substances:

Year:  2013        PMID: 23301633     DOI: 10.1111/adb.12032

Source DB:  PubMed          Journal:  Addict Biol        ISSN: 1355-6215            Impact factor:   4.280


  8 in total

Review 1.  An Animal Model of Alcohol Dependence to Screen Medications for Treating Alcoholism.

Authors:  H C Becker; M F Lopez
Journal:  Int Rev Neurobiol       Date:  2016-03-10       Impact factor: 3.230

Review 2.  Genes and Alcohol Consumption: Studies with Mutant Mice.

Authors:  J Mayfield; M A Arends; R A Harris; Y A Blednov
Journal:  Int Rev Neurobiol       Date:  2016       Impact factor: 3.230

3.  Adenosinergic regulation of striatal clock gene expression and ethanol intake during constant light.

Authors:  Christina L Ruby; Chelsea A Vadnie; David J Hinton; Osama A Abulseoud; Denise L Walker; Katheryn M O'Connor; Maria F Noterman; Doo-Sup Choi
Journal:  Neuropsychopharmacology       Date:  2014-04-23       Impact factor: 7.853

4.  Adenosinergic regulation of binge-like ethanol drinking and associated locomotor effects in male C57BL/6J mice.

Authors:  Brandon M Fritz; Stephen L Boehm
Journal:  Pharmacol Biochem Behav       Date:  2015-05-29       Impact factor: 3.533

Review 5.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

6.  Activation of adenosine A₂A receptors suppresses the emission of pro-social and drug-stimulated 50-kHz ultrasonic vocalizations in rats: possible relevance to reward and motivation.

Authors:  Nicola Simola; Giulia Costa; Micaela Morelli
Journal:  Psychopharmacology (Berl)       Date:  2015-11-13       Impact factor: 4.530

7.  Postsynaptic adenosine A2A receptors modulate intrinsic excitability of pyramidal cells in the rat basolateral amygdala.

Authors:  Andrew R Rau; Olusegun J Ariwodola; Jeff L Weiner
Journal:  Int J Neuropsychopharmacol       Date:  2015-02-25       Impact factor: 5.176

Review 8.  Adenosine A2AReceptors in Substance Use Disorders: A Focus on Cocaine.

Authors:  Karolina Wydra; Dawid Gawliński; Kinga Gawlińska; Małgorzata Frankowska; Dasiel O Borroto-Escuela; Kjell Fuxe; Małgorzata Filip
Journal:  Cells       Date:  2020-06-01       Impact factor: 6.600

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.